Today, we are excited to announce AlphaGenome 2, our next-generation model that predicts how DNA sequences and their variations impact specific human cell types and states, giving scientists a powerful new tool to uncover the molecular drivers of disease.
Key Features & Highlights:
-
Conditional cell-type model architecture: Fundamentally redesigned to predict molecular effects of a target “condition”, which can be a tissue, cell type, or a cell state, accurately capturing subtle differences across cell types.
-
Generalization without fine-tuning: Analyzes unseen single-cell experiments and cell states by conditioning on gene transcription without fine-tuning, allowing users to make predictions for a defined cell state, specific to their data.
-
Cross-modality imputation: Enables prediction of missing experimental data from a single input measurement like single-cell gene activity.
-
State-of-the-art variant effect prediction: Identifies nearly twice as many causal variants (30% vs 16%) and directional gene effects in primary immune cells compared to previous models.
-
DNA methylation predictions: As one of our most requested readouts after the release of AlphaGenome, we are happy to share that AlphaGenome 2 supports methylation predictions!
-
Bridging GWAS and single-cell biology: Precomputed variant predictions map enhancer-gene links in primary human cell types and pinpoint causal disease-associated variants across complex traits.
Read the pre-print and our blog
Access AlphaGenome 2 API
We are excited to share AlphaGenome 2 with the research community and look forward to your feedback and insights! As always, if you have any questions about using the new model please ask us here!
We’re also planning to bring AlphaGenome 2 to our commercial users soon. Please get in touch with your Google Cloud account rep (or if you don’t have one - email us on alphagenome@google.com) to express interest for commercial use.
We’d love to spotlight interesting AlphaGenome 2 use cases the community can learn from. Get in touch via this form by 30 November; selected projects may be eligible for additional quota and credits. We also want to be guided by community input to shape our future roadmap, please share your feedback and ideas in our community forum.